The patent, which covers the process for the preparation of the compounds and their pharmaceutical composition, includes RX-5902, a p68 helicase inhibitor, available in oral dosage form.
RX-5902, in addition to exhibiting antitumor properties in several types of tumors, possess strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs.
Rexahn Pharmaceuticals president Rick Soni said with the issuance of the patent, the company has gained the intellectual property protection for Quinoxalinyl-piperazine derivatives.
"This patent is significant step forward in the development of RX-5902, and further strengthens our overall global intellectual property position in oncology," Soni added.
Previously, patents were awarded for quinoxalinyl-piperazine compounds in Europe, Australia, Canada and Mexico, the company said.